314 Matching Annotations
  1. Last 7 days
    1. Siddle, K. J., Krasilnikova, L. A., Moreno, G. K., Schaffner, S. F., Vostok, J., Fitzgerald, N. A., Lemieux, J. E., Barkas, N., Loreth, C., Specht, I., Tomkins-Tinch, C. H., Silbert, J., Schaeffer, B., Taylor, B. P., Loftness, B., Johnson, H., Schubert, P. L., Shephard, H. M., Doucette, M., … Sabeti, P. C. (2021). Evidence of transmission from fully vaccinated individuals in a large outbreak of the SARS-CoV-2 Delta variant in Provincetown, Massachusetts (p. 2021.10.20.21265137). https://doi.org/10.1101/2021.10.20.21265137

  2. Oct 2021
    1. Vöhringer, H. S., Sanderson, T., Sinnott, M., De Maio, N., Nguyen, T., Goater, R., Schwach, F., Harrison, I., Hellewell, J., Ariani, C. V., Gonçalves, S., Jackson, D. K., Johnston, I., Jung, A. W., Saint, C., Sillitoe, J., Suciu, M., Goldman, N., Panovska-Griffiths, J., … Gerstung, M. (2021). Genomic reconstruction of the SARS-CoV-2 epidemic in England. Nature, 1–11. https://doi.org/10.1038/s41586-021-04069-y

    1. Mlcochova, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Ferreira, I. A. T. M., Datir, R., Collier, D. A., Albecka, A., Singh, S., Pandey, R., Brown, J., Zhou, J., Goonawardane, N., Mishra, S., Whittaker, C., Mellan, T., Marwal, R., Datta, M., … Gupta, R. K. (2021). SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature, 1–6. https://doi.org/10.1038/s41586-021-03944-y

    1. Barros-Martins, J., Hammerschmidt, S. I., Cossmann, A., Odak, I., Stankov, M. V., Morillas Ramos, G., Dopfer-Jablonka, A., Heidemann, A., Ritter, C., Friedrichsen, M., Schultze-Florey, C., Ravens, I., Willenzon, S., Bubke, A., Ristenpart, J., Janssen, A., Ssebyatika, G., Bernhardt, G., Münch, J., … Behrens, G. M. N. (2021). Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nature Medicine, 1–5. https://doi.org/10.1038/s41591-021-01449-9

  3. Sep 2021
    1. Krause, P. R., Fleming, T. R., Peto, R., Longini, I. M., Figueroa, J. P., Sterne, J. A. C., Cravioto, A., Rees, H., Higgins, J. P. T., Boutron, I., Pan, H., Gruber, M. F., Arora, N., Kazi, F., Gaspar, R., Swaminathan, S., Ryan, M. J., & Henao-Restrepo, A.-M. (2021). Considerations in boosting COVID-19 vaccine immune responses. The Lancet, 4. https://doi.org/10.1016/S0140-6736(21)02046-8

    1. Twohig, K. A., Nyberg, T., Zaidi, A., Thelwall, S., Sinnathamby, M. A., Aliabadi, S., Seaman, S. R., Harris, R. J., Hope, R., Lopez-Bernal, J., Gallagher, E., Charlett, A., Angelis, D. D., Presanis, A. M., Dabrera, G., Koshy, C., Ash, A., Wise, E., Moore, N., … Gunson, R. (2021). Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: A cohort study. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00475-8

    1. Kraemer, M. U. G., Hill, V., Ruis, C., Dellicour, S., Bajaj, S., McCrone, J. T., Baele, G., Parag, K. V., Battle, A. L., Gutierrez, B., Jackson, B., Colquhoun, R., O’Toole, Á., Klein, B., Vespignani, A., COVID-19 Genomics UK (COG-UK) Consortium‡, Volz, E., Faria, N. R., Aanensen, D. M., … Pybus, O. G. (2021). Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence. Science, 373(6557), 889–895. https://doi.org/10.1126/science.abj0113

  4. Aug 2021
    1. Tim Plante, MD MHS on Twitter: “Just reported: About half of recent ICU patients with #Covid19 in #Vermont are vaccinated. Sounds like the vaccines aren’t working, right? WRONG. Vaccines are working and here’s why. But first, let’s talk a bit about unprotected sex. A thread. (Refs at the end.) 1/n https://t.co/iyQcfCDAfh” / Twitter. (n.d.). Retrieved August 27, 2021, from https://twitter.com/tbplante/status/1430222978961317896

    1. Liu, Y., Arase, N., Kishikawa, J., Hirose, M., Li, S., Tada, A., Matsuoka, S., Arakawa, A., Akamatsu, K., Ono, C., Jin, H., Kishida, K., Nakai, W., Kohyama, M., Nakagawa, A., Yamagishi, Y., Nakagami, H., Kumanogoh, A., Matsuura, Y., … Arase, H. (2021). The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines (p. 2021.08.22.457114). https://doi.org/10.1101/2021.08.22.457114

    1. Prof. Christina Pagel on Twitter: “THREAD latest on B.1.617.2 variant in England: B.1.617.2 (1st discovered in India) is now dominant in England. Here is a thread summarising latest PHE report and Sanger local data. TLDR: it is NOT good news. 1/7” / Twitter. (n.d.). Retrieved August 24, 2021, from https://twitter.com/chrischirp/status/1399333330286415876

    1. Carl T. Bergstrom. (2021, August 18). 1. There has been lots of talk about recent data from Israel that seem to suggest a decline in vaccine efficacy against severe disease due to Delta, waning protection, or both. This may have even been a motivation for Biden’s announcement that the US would be adopting boosters. [Tweet]. @CT_Bergstrom. https://twitter.com/CT_Bergstrom/status/1427767356600688646

    1. Madhi, S. A., Koen, A. L., Izu, A., Fairlie, L., Cutland, C. L., Baillie, V., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., Briner, C., Aley, P. K., Bhikha, S., Hermanus, T., Horne, E., Jose, A., Kgagudi, P., Lambe, T., Masenya, M., … Kwatra, G. (2021). Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: An interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. The Lancet HIV, 0(0). https://doi.org/10.1016/S2352-3018(21)00157-0

    1. Denise Dewald, MD 🗽. (2021, August 12). Here are some modeling predictions for the delta variant from COVSIM (group at North Carolina State): PLEASE CHECK THIS OUT - RESOURCES TO SHARE WITH YOUR SCHOOL DISTRICT School-level COVID-19 Modeling Results for North Carolina for #DeltaVariant https://t.co/zU5hB9bKlY [Tweet]. @denise_dewald. https://twitter.com/denise_dewald/status/1425626289399009288

    1. Kai Kupferschmidt on Twitter: “One of the most important things I was looking for in reporting on #SARSCoV2 evolution was a way of making sense of all the virus variants, putting them in some framework. And one of the most useful things I found for that is this antigenic map. It’s worth explaining a bit: Https://t.co/miO8Kh9w9e” / Twitter. (n.d.). Retrieved August 22, 2021, from https://twitter.com/kakape/status/1428650961652916230?s=20

    1. Marc Lipsitch. (2021, July 20). At the risk of boiling down too much and certainly losing some detail, one way to summarize this wonderful thread is that when we think about vaccine effectiveness, we should think of 4 key variables: 1 which vaccine, 2 age of the person, 3 how long after vax, 4 vs what outcome. [Tweet]. @mlipsitch. https://twitter.com/mlipsitch/status/1417595538632060931

    1. André Picard on Twitter: “Most of those numbers are in the column, which focuses on a) the risk of the Delta variant to children under 12 and b) the 29% of Canadians who are not fully vaccinated. Brace yourself for more COVID-19 nastiness https://t.co/V0agVYvKRx” / Twitter. (n.d.). Retrieved August 13, 2021, from https://twitter.com/picardonhealth/status/1425316861176995840

    1. Craig Spencer MD MPH. (2021, August 6). Even with Delta, the likelihood of severe illness if you’re fully immunized is still a small fraction of the likelihood for the unvaccinated. In other words, nearly every COVID-19-related death right now is preventable with vaccination. [Tweet]. @Craig_A_Spencer. https://twitter.com/Craig_A_Spencer/status/1423674337089949710

    1. Rafael Irizarry. (2021, August 8). Vaccines work in a gif update: COVID19 cases versus vaccination rates in US states through time. The Delta variant effect can be seen clearly starting in July. States with lower vaccination rates are affected much worse. Https://t.co/e0SQpa8Qg0 [Tweet]. @rafalab. https://twitter.com/rafalab/status/1424440520361787392

  5. www.newscientist.com www.newscientist.com